Neflamapimod for Lewy Body Dementia
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial is testing neflamapimod, a drug that may help improve thinking and memory skills. It targets people with Dementia with Lewy Bodies (DLB), who often struggle with these issues. The drug works by reducing inflammation in the brain.
Will I have to stop taking my current medications?
The trial requires that you are not currently taking cholinesterase inhibitors unless you have been on a stable dose for at least 6 weeks. If you previously took cholinesterase inhibitors, you must have stopped at least 3 months before joining. Memantine is allowed if started at least 3 months prior and you are also on cholinesterase inhibitors, or as monotherapy if you have never taken cholinesterase inhibitors.
Is Neflamapimod safe for humans?
What makes the drug Neflamapimod unique for treating Lewy Body Dementia?
Neflamapimod is unique because it is being investigated as a potential disease-modifying treatment for Lewy Body Dementia, unlike current options that mainly focus on symptom relief. This drug is in phase II trials and shows promising results, which is significant given the lack of FDA-approved treatments specifically for this condition.12346
What data supports the effectiveness of the drug Neflamapimod for Lewy Body Dementia?
Are You a Good Fit for This Trial?
This trial is for individuals aged ≥55 with Dementia with Lewy Bodies (DLB), who have received a positive DaTscan™ or have REM sleep behavioral disorder, and are on stable cholinesterase inhibitor therapy. They must be vaccinated against COVID-19, not suffer from other CNS conditions like Alzheimer's or Parkinson's, and should not have major psychiatric disorders or recent drug abuse history.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive neflamapimod or placebo for 16 weeks to assess improvements in cognitive and motor functions
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Neflamapimod
Find a Clinic Near You
Who Is Running the Clinical Trial?
EIP Pharma Inc
Lead Sponsor
Worldwide Clinical Trials
Collaborator
National Institute on Aging (NIA)
Collaborator
CervoMed, Inc
Collaborator